Medical Therapy. Efficacy or Lack of Efficacy

Michael W. Cookson, John P. KinsellaUniversity of Colorado Anschutz School of Medicine and Children’s Hospital Colorado.United States Clinics in PerinatologyClin Perinatol 2024; 51: 95-111DOI: 10.1016/j.clp.2023.11.001 AbstractPivotal trials investigating the use of inhaled nitric oxide (iNO) in the 1990s led to approval by the Food and Drug Administration in 1999. Inhaled nitric oxide is the only approved

Kristen Coletti, K. Taylor Wild, Elizabeth E. Foglia, Suzan Cochius-den Otter, Haresh KirpalaniChildren’s Hospital of Philadelphia and University of Pennsylvania. Erasmus MC University Medical Center.United States and Netherlands Clinics in PerinatologyClin Perinatol 2024; 51: 253-269DOI: 10.1016/j.clp.2023.11.009 AbstractInhaled nitric oxide (iNO) is a pulmonary vasodilator considered standard of care to treat persistent pulmonary hypertension of the newborn.

Jeanne Carroll, Rohit Rao, Robin H. SteinhornUniversity of California, San Diego and Rady Children’s Hospital. United States Clinics in PerinatologyClin Perinatol 2024; 51: 113-126DOI: 10.1016/j.clp.2023.11.008 AbstractPulmonary hypertension in the neonatal population can be acute or chronic and carries significant risk for morbidity and mortality. It can be idiopathic but more often is associated with comorbid pulmonary